A Study of Outcomes and Toxicity of Busulfex as Part of a High Dose Chemotherapy Preparative Regimen in Autologous Hematopoietic Stem Cell Transplantation for Patients With Plasma Cell Myeloma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 May 2017
At a glance
- Drugs Busulfan (Primary) ; Cyclophosphamide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 13 May 2017 Planned End Date changed from 1 Feb 2013 to 1 May 2018.
- 04 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 04 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.